#ANV419
HomeTag: #ANV419
Anaveon presents updated data from the Phase I/II study of ANV419 during the ESMO Congress 2022

Anaveon presents updated data from the Phase I/II study of ANV419 during the ESMO Congress 2022

by | Sep 10, 2022 | Press Releases

Anaveon, a clinical-stage immuno-oncology company, today announces updated clinical data from the ongoing Phase I/II study of ANV419 in patients with solid tumors, as well as new pre-clinical data further elucidating the mode of action of this powerful and selective interleukin-2 (IL-2) agonist, in poster presentations at the European Society for Medical Oncology (ESMO) Congress 2022, taking place in Paris, September 9 – 13, 2022.